Table 2.

Drug‐dependent system parameters

Description	Parameter	Rat			Human
		Unit	Value	CV (%)	IC50 scaled value
Carboplatin effects in multipotent progenitors	SlopeMPP	1/μM	2.05	11.8	0.79
Carboplatin effects in common myeloid progenitors	SlopeCMP	1/μM	1.47	8.6	0.57
Carboplatin effects in megakaryocyte–erythrocyte progenitors	SlopeMEP	1/μM	2.19	10.3	0.66
Carboplatin effects in reticulocyte proliferating transit‐compartments	δRet	Dimensionless	2.8	21	2.8 (as in rat)
Carboplatin effects in platelet proliferating transit compartments	δPlt	Dimensionless	0.54	30.4	0.54 (as in rat)

Carboplatin effects in rat were estimated by fitting the model to the data. Human values were calculated by adjusting the rat values for species‐specific drug sensitivity ${\left({\text{Slope}}_{\mathrm{H},\mathrm{IC}50}={\text{Slope}}_{\mathrm{R}}\times \frac{\text{IC}{50}_{\mathrm{H}}}{\text{IC}{50}_{\mathrm{R}}}\right)}^{-1}$, Eq. (10). The IC50 values used to scale drug effects are reported in Table S3 . Coefficient of variation (CV%) values show the confidence in our parameter estimates. IC50, half maximal inhibitory concentration.